@vmemarketingtest.bsky.social
Thank you for joining us!
Click here to compete in GameOn! Challenge to test your knowledge and confidence regarding drug–drug interactions in COVID-19 outpatient management
Click here to compete in GameOn! Challenge to test your knowledge and confidence regarding drug–drug interactions in COVID-19 outpatient management
March 3, 2025 at 7:51 PM
Thank you for joining us!
Click here to compete in GameOn! Challenge to test your knowledge and confidence regarding drug–drug interactions in COVID-19 outpatient management
Click here to compete in GameOn! Challenge to test your knowledge and confidence regarding drug–drug interactions in COVID-19 outpatient management
Ritonavir-boosted nirmatrelvir is a CYP3A inhibitor;🚫 with drugs metabolized by CYP3A & where ⬆️ concentrations could have serious effects/strong CYP3A inducers (⬇️ nirmatrelvir/ritonavir plasma concentrations could = virologic response loss or resistance). 👇
March 3, 2025 at 7:51 PM
Ritonavir-boosted nirmatrelvir is a CYP3A inhibitor;🚫 with drugs metabolized by CYP3A & where ⬆️ concentrations could have serious effects/strong CYP3A inducers (⬇️ nirmatrelvir/ritonavir plasma concentrations could = virologic response loss or resistance). 👇
The CDC recommends ritonavir-boosted nirmatrelvir (Paxlovid) or remdesivir (Veklury) for the treatment of COVID-19 among patients who are at high risk of progressing to severe COVID-19.
An alternative therapy is molnupiravir (Lagevrio).
An alternative therapy is molnupiravir (Lagevrio).
March 3, 2025 at 7:51 PM
The CDC recommends ritonavir-boosted nirmatrelvir (Paxlovid) or remdesivir (Veklury) for the treatment of COVID-19 among patients who are at high risk of progressing to severe COVID-19.
An alternative therapy is molnupiravir (Lagevrio).
An alternative therapy is molnupiravir (Lagevrio).